Inhibition of glycogen synthase kinase-3 (GSK3) promotes the neural differentiation of full-term amniotic fluid-derived stem cells towards neural progenitor cells

Gao, Liyang; Zhao, Mingyan; Ye, Wei; Huang, Jinzhi; Chu, Jiaqi; Yan, Shouquan; Wang, Chaojun; Zeng, Rong

doi:10.1016/j.tice.2016.06.001

Cited by 8 publications

(7 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to the stem cell marker CD117, and the mesenchymal stem cell marker CD73, the presence of cell surface makers: CD90 and CD105 were correlated with a higher potential to provide protection to the developing fetal brain, as measured by brain lesion size reduction after injection of either spindle‐shaped or round‐shaped AFSCs in animal models of hypoxic ischemic encephalopathy 33 . CD117+ AFSCs showed success for differentiation into neural progenitor cells, as measured by a neuronal progenitor marker, NESTIN, in vitro with addition of GSK3‐beta inhibitor, SB21676 34 . In addition, the CD117+ AFSCs selected for neural differentiation were shown to have higher expression of CD73 and CD90 relative to nonselected cells 34 .…”

Section: Discussionmentioning

confidence: 99%

Amniotic fluid‐derived stem cell potential for therapeutic and surgical use: A review of the literature

2022

View full text Add to dashboard Cite

Objective Spina bifida is a debilitating neutral tube defect affecting many infants. The impact and severity of spina bifida depends on whether the patient exhibits a closed defect, spina bifida occulta, or an open defect, spina bifida aperta. Patients with spina bifida have physical and mental disabilities which merit further research into less invasive, more successful treatments. In addition to serving as protection for the growing fetus and facilitating nutrient exchange, amniotic fluid (AF) is a rich source of a mixed population of stem cells. As such, in vitro culture of AF‐derived stem cells has shown promise among therapeutic and surgical applications. We present a critical evaluation of the current preclinical efforts, amniotic fluid‐derived stem cell (AFSC) culture process, and the subsequent therapeutic application, with a focus on improvements for spina bifida outcomes in the pediatric patient population. Method An evidence ‐ based literature review to investigate the current literature surrounding AFSC culture and use, with an emphasis on the benefits for spina bifida treatment. Results 47 literature sources from PubMed and three studies from ClinicalTrials.gov. Conclusion This review synthesizes the current literature, which shows promising data on AFSC pluripotency, as well as successful in utero coverage from AFSC ‐ supported environments in a multitude of animal models.

show abstract

Section: Discussionmentioning

confidence: 99%

Amniotic fluid‐derived stem cell potential for therapeutic and surgical use: A review of the literature

2022

View full text Add to dashboard Cite

show abstract

“…There is evidence that indicates that amniotic fluid derived stem cells are able to differentiate into neural cells given the correct conditions that can induce the differentiation. Nevertheless, until this study, the neural differentiation of human amniotic fluid derived stem cells effectiveness and efficiency has remained low [13].…”

Section: Inhibition Of Gsk3β To Differentiate Amniotic Stem Cells Into Neural Progenitor Cellsmentioning

confidence: 93%

“…This finding provides insight on an efficient and cost effective method to induce and maintain proliferation of human amniotic stem cells, along with inducing the differentiation of neural progenitor cells from hAFS cells. Learning more about the induction of neural differentiation from amniotic stem cells may provide possible treatment options for neurodegenerative diseases [13].…”

Section: Inhibition Of Gsk3β To Differentiate Amniotic Stem Cells Into Neural Progenitor Cellsmentioning

confidence: 99%

Use of Amniotic Stem Cells to Promote New Medical Treatments and Advancements in Regenerative Medicine

Hisrich¹,

Gallicchio²

2017

Madridge J Clin Res

View full text Add to dashboard Cite

“…In fact, one of the best-defined functions of PrP C is its antioxidant activity though different means, including copper homeostasis [29], modulation of endogenous superoxide dismutase (SOD) [30], and glutathione reductase (GR) activities [31]. Nevertheless, an increasing number of studies suggest that PrP C is involved in neuronal differentiation of neural progenitors from different stem cells populations [32][33][34], a process strongly influenced by GSK3 activity [35]. In this sense, PrP C triggers in vivo reduction of GSK3β kinase activity through phosphorylation of GSK3β on serine 9 residue [36].…”

Section: Introductionmentioning

confidence: 99%

Tau Exon 10 Inclusion by PrPC through Downregulating GSK3β Activity

Lidón

Llaó-Hierro

Aguzzi

et al. 2021

IJMS

View full text Add to dashboard Cite

Tau protein is largely responsible for tauopathies, including Alzheimer’s disease (AD), where it accumulates in the brain as insoluble aggregates. Tau mRNA is regulated by alternative splicing, and inclusion or exclusion of exon 10 gives rise to the 3R and 4R isoforms respectively, whose balance is physiologically regulated. In this sense, one of the several factors that regulate alternative splicing of tau is GSK3β, whose activity is inhibited by the cellular prion protein (PrPC), which has different physiological functions in neuroprotection and neuronal differentiation. Moreover, a relationship between PrPC and tau expression levels has been reported during AD evolution. For this reason, in this study we aimed to analyze the role of PrPC and the implication of GSK3β in the regulation of tau exon 10 alternative splicing. We used AD human samples and mouse models of PrPC ablation and tau overexpression. In addition, we used primary neuronal cultures to develop functional studies. Our results revealed a paralleled association between PrPC expression and tau 4R isoforms in all models analyzed. In this sense, reduction or ablation of PrPC levels induces an increase in tau 3R/4R balance. More relevantly, our data points to GSK3β activity downstream from PrPC in this phenomenon. Our results indicate that PrPC plays a role in tau exon 10 inclusion through the inhibitory capacity of GSK3β.

show abstract

Inhibition of glycogen synthase kinase-3 (GSK3) promotes the neural differentiation of full-term amniotic fluid-derived stem cells towards neural progenitor cells

Cited by 8 publications

References 58 publications

Amniotic fluid‐derived stem cell potential for therapeutic and surgical use: A review of the literature

Amniotic fluid‐derived stem cell potential for therapeutic and surgical use: A review of the literature

Use of Amniotic Stem Cells to Promote New Medical Treatments and Advancements in Regenerative Medicine

Tau Exon 10 Inclusion by PrPC through Downregulating GSK3β Activity

Contact Info

Product

Resources

About